当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第1期, 第74-76页
标题:
临床药师参与一例心房颤动合并慢性肾脏病病人的抗凝治疗
DOI:
10.5428/pcar20190118
作者:
1. 杨锦艳(山西晋城无烟煤矿业集团有限责任公司总医院药学部 山西晋城 048006 yangjy185900@163.com)
2. 贾晋生(山西晋城无烟煤矿业集团有限责任公司总医院药学部 山西晋城 048006 1329019376@qq.com)
摘要:
欢迎阅读《药学服务与研究》!您是该文第 107 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 杨锦艳,贾晋生. 临床药师参与一例心房颤动合并慢性肾脏病病人的抗凝治疗[J]. 药学服务与研究. 2019; 19(1): 74-76.
英文著录格式 YANG Jinyan,JIA Jinsheng. Pharmacists involvement in anticoagulant treatment of a patient with atrial fibrillation complicated with chronic kidney disease[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 74-76.
参考文献:
1. Providência R,Marijon E,Boveda S,et al.Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation[J].Am J Cardiol,2014,114(4):646-653.
2. Friberg L,Benson L,Lip G Y.Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study[J].Eur Heart J,2015,36(5):297-306.
3. January C T,Wann L S,Alpert J S,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130(23):e199-e267.
4. Bautista J,Bella A,Chaudhari A,et al.Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure[J].Clin Kidney J,2015,8(2):226-231.
5. Schwartzenberg S,Lev E I,Sagie A,et al.The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease[J].Am J Cardiol,2016,117(3):477-482.
6. 马文芳,梁岩.心房颤动抗凝出血风险评估进展[J].心血管病学进展,2017,38(6):639-643.
7. Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Eur J Cardiothorac Surg,2016,50(5):e1-e88
8. Olesen J B,Lip G Y,Kamper A L,et al.Stroke and bleeding in atrial fibrillation with chronic kidney disease[J].N Engl J Med,2012,367(7):625-635.
9. Sakaan S A,Hudson J Q,Oliphant C S,et al.Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease[J].Pharmacotherapy,2014,34(7):695-702.
10. Agewall S,Cattaneo M,Collet J P,et al.Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J].Eur Heart J,2013,34(23):1708-1713,1713a-1713b.
11. Naganuma M,Shiga T,Nishikata K,et al.Role of desethylamiodarone in the anticoagulan effect of concurrent amiodarone and warfarin therapy[J].J Cardiovasc Pharmacol Ther,2001,6(4):363-367.